pI: 6.6919 |
Length (AA): 418 |
MW (Da): 45168 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 2 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
16 | 52 | 2kpy (A) | 69 | 106 | 49.00 | 0.077 | 0.06 | 0.482142 | 0.17 |
77 | 362 | 4w7g (A) | 45 | 376 | 17.00 | 0 | 1 | 0.8034 | -0.56 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_131077)
Species | Accession | Gene Product |
---|---|---|
Brugia malayi | Bm1_12090 | hypothetical protein |
Brugia malayi | Bm1_22100 | dynein 2 light intermediate chain |
Caenorhabditis elegans | CELE_F02D8.3 | Protein XBX-1 |
Drosophila melanogaster | Dmel_CG3769 | CG3769 gene product from transcript CG3769-RA |
Echinococcus granulosus | EgrG_000475500 | Dynein intermediate chain |
Echinococcus granulosus | EgrG_000475600 | Dynein intermediate chain |
Echinococcus multilocularis | EmuJ_000475600 | Dynein intermediate chain |
Echinococcus multilocularis | EmuJ_000475500 | Dynein intermediate chain |
Homo sapiens | ENSG00000138036 | dynein, cytoplasmic 2, light intermediate chain 1 |
Leishmania braziliensis | LbrM.32.3520 | dynein light intermediate chain, putative |
Leishmania donovani | LdBPK_323430.1 | dynein light intermediate chain, putative |
Leishmania infantum | LinJ.32.3430 | dynein light intermediate chain, putative |
Leishmania major | LmjF.32.3230 | dynein light intermediate chain, putative |
Leishmania mexicana | LmxM.31.3230 | dynein light intermediate chain, putative |
Loa Loa (eye worm) | LOAG_12144 | hypothetical protein |
Mus musculus | ENSMUSG00000024253 | dynein cytoplasmic 2 light intermediate chain 1 |
Onchocerca volvulus | OVOC7345 | Cytoplasmic dynein 2 light intermediate chain 1 homolog |
Onchocerca volvulus | OVOC7272 | Cytoplasmic dynein 2 light intermediate chain 1 homolog |
Schistosoma japonicum | Sjp_0207550 | ko:K10417 dynein light intermediate chain 2, cytosolic, putative |
Schistosoma mansoni | Smp_159340 | hypothetical protein |
Schmidtea mediterranea | mk4.001573.06 | Cytoplasmic dynein 2 light intermediate chain 1 |
Trypanosoma brucei gambiense | Tbg972.11.18970 | dynein light intermediate chain, putative |
Trypanosoma brucei | Tb927.11.16810 | dynein light intermediate chain D1bLIC, putative |
Trypanosoma cruzi | TcCLB.511025.10 | dynein light intermediate chain, putative |
Trypanosoma cruzi | TcCLB.511533.19 | dynein light intermediate chain, putative |
Trypanosoma cruzi | TcCLB.503927.9 | dynein light intermediate chain, putative |
Trichomonas vaginalis | TVAG_407890 | dynein light intermediate chain, putative |
Trichomonas vaginalis | TVAG_277480 | conserved hypothetical protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.01.8570 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb11.01.8570 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb11.01.8570 this record | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb11.01.8570 this record | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | decreased (PATO:0000468) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | decreased (PATO:0000468) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
1 literature reference was collected for this gene.